|
시장보고서
상품코드
2149242
척추 바이오로직스 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)Spine Biologics Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
척추용 바이오의약품 시장 성장요인
세계 척추용 바이오의약품 시장 규모는 2025년 36억 5,000만 달러로 평가되며, 2026년 38억 8,000만 달러에서 2034년까지 65억 달러로 성장할 것으로 예상되며, 예측 기간 동안 연평균 성장률(CAGR)은 6.65%에 달할 것으로 전망됩니다. 2025년, 북미는 45.75%의 점유율을 차지하며 전 세계 척추용 바이오의약품 시장을 주도했습니다. 척추용 바이오로직스란 척추 수술 시 뼈의 치유 및 유합을 촉진하기 위해 사용되는 물질을 말합니다. 척추 질환의 증가, 수술 건수의 증가, 그리고 최소침습 수술의 보급이 첨단 바이오로직스 제품에 대한 수요를 뒷받침하고 있습니다.
또한, 주요 기업 간의 제품 혁신, 전략적 제휴 및 인수합병도 시장 성장을 뒷받침하고 있습니다. 동종 이식편, 탈회골 매트릭스, 합성 이식편, 골수 흡인 농축액, 성장 인자 및 세포 기반 매트릭스의 사용이 증가함에 따라, 척추 수술에 활용할 수 있는 바이오로직스 솔루션의 선택 폭이 넓어지고 있습니다.
시장의 정의 및 범위
척추용 바이오로직스란 척추 수술에서 뼈 재생을 촉진하고, 골유합을 지원하며, 치유를 개선하기 위해 사용되는 생물 유래 및 합성 재료를 의미합니다. 이 시장에는 골 이식 대체재, 혈소판 농축 혈장, 성장 인자, 세포 기반 매트릭스 및 골수 천자 농축액이 포함됩니다. 그 용도에는 병원, 외래 수술 센터 및 척추 전문 클리닉에서의 척추 고정술, 비고정술, 골절 교정, 척추측만증 교정 등이 포함됩니다.
시장 역학
촉진요인 - 척추 수술 건수 증가 : 척추 퇴행성 질환의 발생률 증가가 척추 고정술 및 기타 생체 재료를 필요로 하는 수술에 대한 수요를 견인하고 있습니다. 경추 및 요추 수술 건수의 증가로 인해 동종 이식편, DBM(탈회골), 합성 이식편 및 세포 기반 제품에 대한 지속적인 수요가 발생하고 있습니다.
억제요인 - 보험 지급 제도의 불균일성 : 의료 제도별 보험 지급 정책의 차이로 인해 고가의 생체 재료 제품 채택이 제한될 가능성이 있습니다. 보험 적용 범위의 제한으로 인해 의료 제공자는 저비용 대체품을 선택하는 경향이 있으며, 이는 새로운 생체 재료 솔루션의 보급에 영향을 미치고 있습니다.
기회 - 세포 유래 및 재생의학용 생체재료 : 줄기세포를 이용한 이식재, 재생용 스캐폴드, 생체 골 매트릭스 및 세포 기반 기술의 발전으로 인해, 골 재생의 개선과 보다 예측 가능한 척추 고정술의 결과가 기대되는 기회가 창출되고 있습니다.
동향 - 최소침습 척추 수술 : 최소침습 수술의 채택이 증가함에 따라, 취급이 용이하고 더 작은 수술 절개 부위를 통해 투여할 수 있는 생물학적 제제에 대한 수요가 높아지고 있습니다. 최소침습 수술(MIS)용으로 특별히 설계된 새로운 투여 시스템이 이러한 동향을 뒷받침하고 있습니다.
과제 - 동종 이식편의 한계 : 기증자 확보의 불안정성, 생물학적 변동성, 멸균 과정에 따른 변화, 제한된 골형성 능력 등이 동종 이식편의 성능에 영향을 미칠 수 있습니다. 이러한 한계로 인해 차세대 생물학적 대체재의 개발과 도입이 촉진되고 있습니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 역학
제4장 주요 인사이트
제5장 세계의 척추 바이오로직스 시장 분석, 인사이트, 예측, 2021-2034년
제6장 북미의 척추 바이오로직스 시장 분석, 인사이트, 예측, 2021-2034년
제7장 유럽의 척추 바이오로직스 시장 분석, 인사이트, 예측, 2021-2034년
제8장 아시아태평양의 척추 바이오로직스 시장 분석, 인사이트, 예측, 2021-2034년
제9장 라틴아메리카의 척추 바이오로직스 시장 분석, 인사이트, 예측, 2021-2034년
제10장 중동 및 아프리카의 척추 바이오로직스 시장 분석, 인사이트, 예측, 2021-2034년
제11장 경쟁 분석
KSM 26.10.22Growth Factors of spine biologics Market
The global spine biologics market size was valued at USD 3.65 billion in 2025 and is projected to grow from USD 3.88 billion in 2026 to USD 6.50 billion by 2034, registering a CAGR of 6.65% during the forecast period. North America dominated the global spine biologics market with a 45.75% share in 2025. Spine biologics are substances used during spinal procedures to promote bone healing and fusion. Rising spinal disorders, increasing surgical procedures, and the adoption of minimally invasive techniques are supporting demand for advanced biologic products.
The market is further supported by product innovation, strategic collaborations, and acquisitions among major companies. The increasing use of allografts, demineralized bone matrix, synthetic grafts, bone marrow aspirate concentrates, growth factors, and cell-based matrices is expanding the range of biologic solutions available for spinal procedures.
Market Definition and Scope
Spine biologics comprise biological and synthetic materials used in spinal surgery to stimulate bone regeneration, support fusion, and improve healing. The market includes bone graft substitutes, platelet-rich plasma, growth factors, cell-based matrices, and bone marrow aspirate concentrates. Applications include spinal fusion, non-fusion procedures, fracture repair, and scoliosis correction across hospitals, ambulatory surgery centers, and specialty spine clinics.
Market Dynamics
Driver - Rising Spinal Surgery Volumes: The increasing incidence of degenerative spine disorders is driving demand for spinal fusion and other procedures requiring biologic materials. High cervical and lumbar procedure volumes are creating sustained demand for allografts, DBM, synthetic grafts, and cell-based products.
Restraint - Reimbursement Variability: Differences in reimbursement policies across healthcare systems can restrict adoption of premium biologic products. Coverage limitations may encourage healthcare providers to select lower-cost alternatives, affecting the uptake of newer biologic solutions.
Opportunity - Cell-Based and Regenerative Biologics: Advances in stem cell-engineered grafts, regenerative scaffolds, viable bone matrices, and cell-based technologies are creating opportunities for improved bone regeneration and potentially more predictable fusion outcomes.
Trend - Minimally Invasive Spine Surgery: The increasing adoption of minimally invasive procedures is creating demand for biologics that are easy to handle and deliver through smaller surgical access points. New delivery systems designed specifically for MIS procedures are supporting this trend.
Challenge - Limitations of Allografts: Inconsistent donor availability, biological variability, sterilization-related changes, and limited osteogenic properties can affect allograft performance. These limitations are encouraging the development and adoption of next-generation biologic alternatives.
Segmentation Analysis
By Product Type: Bone graft substitutes dominated the market in 2025 because of their extensive use in spinal and trauma procedures. The cell-based matrix segment is projected to grow at a CAGR of 9.67%.
By Application: Spinal fusion accounted for the largest share in 2025 and is projected to hold 66.6% in 2026, supported by procedures for degenerative disc disease, spinal trauma, and deformities. Non-fusion procedures are projected to grow at a CAGR of 8.77%.
By End User: Hospitals and ASCs dominated the market in 2025 and are expected to account for 75.9% in 2026, reflecting high surgical volumes and biologic procurement requirements. Specialty orthopedic and spine clinics are projected to grow at a CAGR of 9.12%.
Regional Insights
North America: The region led the market with USD 1.67 billion in 2025. The U.S. market is estimated to reach USD 1.58 billion in 2026, supported by advanced healthcare infrastructure, reimbursement systems, high surgical volumes, and biologic innovation.
Europe: Europe is projected to reach USD 1.12 billion in 2026, with a CAGR of 5.42%. The U.K., Germany, and France are expected to reach USD 0.24 billion, USD 0.21 billion, and USD 0.16 billion, respectively.
Asia Pacific: The region is projected to reach USD 0.76 billion in 2026, with India at USD 0.20 billion and China at USD 0.12 billion, supported by expanding healthcare infrastructure and increasing spinal procedures.
Latin America and Middle East & Africa: Latin America is expected to reach USD 0.15 billion in 2026, while GCC is projected to reach USD 0.04 billion, supported by improvements in surgical infrastructure and product availability.
Competitive Landscape
Major companies include Medtronic, Stryker, Johnson & Johnson, Globus Medical, Xtant Medical, Zimmer Biomet, Biogennix, ChoiceSpine, Biomatlante, and Companion Spine. Companies are strengthening their positions through acquisitions, collaborations, product launches, and expansion of biologic portfolios.
Key Industry Developments
In October 2025, Aurora Spine launched Aurora Biologics. In April 2025, Spine Wave completed a limited market release of Tempest DCF Demineralized Cortical Fibers. Orthofix launched OsteoCove in 2023, while Xtant Medical acquired Surgalign's biologics and spinal fixation business in August 2023 for USD 5.0 million.
Report Coverage
The report covers market size and forecast, product types, applications, end users, regional markets, market dynamics, technological developments, product launches, strategic collaborations, mergers and acquisitions, competitive analysis, and key industry developments.
Conclusion
The global spine biologics market is projected to increase from USD 3.65 billion in 2025 to USD 3.88 billion in 2026 and USD 6.50 billion by 2034, at a CAGR of 6.65%. Rising spinal disorders, increasing fusion procedures, minimally invasive surgery, and advances in regenerative and cell-based biologics will support market expansion. However, reimbursement variability and limitations associated with conventional allografts remain important barriers. Continued product innovation, strategic collaborations, and development of biologics designed for minimally invasive procedures are expected to create further opportunities throughout the forecast period.
Segmentation By Product Type, Application, End User, and Region
By Product Type
- Bone Graft Substitutes
- Allografts
- Demineralized Bone Matrix (DBM)
- Synthetic
- Xenograft
- Platelet Rich Plasma (PRP)
- Growth Factors
- Cell-based Matrices
- Bone Marrow Aspirate Concentrates (BMAC)
- Others
By Application
- Spinal Fusion
- Non-Fusion Procedures
- Fracture Repair
- Scoliosis Correction
- Others
By End User
- Hospitals & ASCs
- Specialty Orthopedic & Spine Clinics
- Others
By Geography
- North America (By Product Type, Application, End User, and Country)
- U.S.
- Canada
- Europe (By Product Type, Application, End User, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Product Type, Application, End User, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Product Type, Application, End User, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Product Type, Application, End User, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Technological Advancements in Spine Biologics
- 4.2. Regulatory Scenario, By Key Countries/Regions
- 4.3. New Product Launches, By Key Players
- 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, among others.)
- 4.5. Key Start-ups in the Market
5. Global Spine Biologics Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Product Type
- 5.1.1. Bone Graft Substitutes
- 5.1.1.1. Allografts
- 5.1.1.2. Demineralized Bone Matrix (DBM)
- 5.1.1.3. Synthetic
- 5.1.1.4. Xenograft
- 5.1.2. Platelet Rich Plasma (PRP)
- 5.1.3. Growth Factors
- 5.1.4. Cell-based Matrices
- 5.1.5. Bone Marrow Aspirate Concentrates (BMAC)
- 5.1.6. Others
- 5.1.1. Bone Graft Substitutes
- 5.2. Market Analysis, Insights and Forecast - By Application
- 5.2.1. Spinal Fusion
- 5.2.2. Non Fusion Procedures
- 5.2.3. Fracture Repair
- 5.2.4. Scoliosis Correction
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast - By End User
- 5.3.1. Hospitals & ASCs
- 5.3.2. Specialty Orthopedic & Spine Clinics
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
6. North America Spine Biologics Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Product Type
- 6.1.1. Bone Graft Substitutes
- 6.1.1.1. Allografts
- 6.1.1.2. Demineralized Bone Matrix (DBM)
- 6.1.1.3. Synthetic
- 6.1.1.4. Xenograft
- 6.1.2. Platelet Rich Plasma (PRP)
- 6.1.3. Growth Factors
- 6.1.4. Cell-based Matrices
- 6.1.5. Bone Marrow Aspirate Concentrates (BMAC)
- 6.1.6. Others
- 6.1.1. Bone Graft Substitutes
- 6.2. Market Analysis, Insights and Forecast - By Application
- 6.2.1. Spinal Fusion
- 6.2.2. Non Fusion Procedures
- 6.2.3. Fracture Repair
- 6.2.4. Scoliosis Correction
- 6.2.5. Others
- 6.3. Market Analysis, Insights and Forecast - By End User
- 6.3.1. Hospitals & ASCs
- 6.3.2. Specialty Orthopedic & Spine Clinics
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Spine Biologics Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Product Type
- 7.1.1. Bone Graft Substitutes
- 7.1.1.1. Allografts
- 7.1.1.2. Demineralized Bone Matrix (DBM)
- 7.1.1.3. Synthetic
- 7.1.1.4. Xenograft
- 7.1.2. Platelet Rich Plasma (PRP)
- 7.1.3. Growth Factors
- 7.1.4. Cell-based Matrices
- 7.1.5. Bone Marrow Aspirate Concentrates (BMAC)
- 7.1.6. Others
- 7.1.1. Bone Graft Substitutes
- 7.2. Market Analysis, Insights and Forecast - By Application
- 7.2.1. Spinal Fusion
- 7.2.2. Non Fusion Procedures
- 7.2.3. Fracture Repair
- 7.2.4. Scoliosis Correction
- 7.2.5. Others
- 7.3. Market Analysis, Insights and Forecast - By End User
- 7.3.1. Hospitals & ASCs
- 7.3.2. Specialty Orthopedic & Spine Clinics
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
8. Asia Pacific Spine Biologics Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Product Type
- 8.1.1. Bone Graft Substitutes
- 8.1.1.1. Allografts
- 8.1.1.2. Demineralized Bone Matrix (DBM)
- 8.1.1.3. Synthetic
- 8.1.1.4. Xenograft
- 8.1.2. Platelet Rich Plasma (PRP)
- 8.1.3. Growth Factors
- 8.1.4. Cell-based Matrices
- 8.1.5. Bone Marrow Aspirate Concentrates (BMAC)
- 8.1.6. Others
- 8.1.1. Bone Graft Substitutes
- 8.2. Market Analysis, Insights and Forecast - By Application
- 8.2.1. Spinal Fusion
- 8.2.2. Non Fusion Procedures
- 8.2.3. Fracture Repair
- 8.2.4. Scoliosis Correction
- 8.2.5. Others
- 8.3. Market Analysis, Insights and Forecast - By End User
- 8.3.1. Hospitals & ASCs
- 8.3.2. Specialty Orthopedic & Spine Clinics
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.4.1. China
- 8.4.2. Japan
- 8.4.3. India
- 8.4.4. Southeast Asia
- 8.4.5. Australia
- 8.4.6. Rest of Asia Pacific
9. Latin America Spine Biologics Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Product Type
- 9.1.1. Bone Graft Substitutes
- 9.1.1.1. Allografts
- 9.1.1.2. Demineralized Bone Matrix (DBM)
- 9.1.1.3. Synthetic
- 9.1.1.4. Xenograft
- 9.1.2. Platelet Rich Plasma (PRP)
- 9.1.3. Growth Factors
- 9.1.4. Cell-based Matrices
- 9.1.5. Bone Marrow Aspirate Concentrates (BMAC)
- 9.1.6. Others
- 9.1.1. Bone Graft Substitutes
- 9.2. Market Analysis, Insights and Forecast - By Application
- 9.2.1. Spinal Fusion
- 9.2.2. Non Fusion Procedures
- 9.2.3. Fracture Repair
- 9.2.4. Scoliosis Correction
- 9.2.5. Others
- 9.3. Market Analysis, Insights and Forecast - By End User
- 9.3.1. Hospitals & ASCs
- 9.3.2. Specialty Orthopedic & Spine Clinics
- 9.3.3. Others
- 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
10. Middle East & Africa Spine Biologics Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Product Type
- 10.1.1. Bone Graft Substitutes
- 10.1.1.1. Allografts
- 10.1.1.2. Demineralized Bone Matrix (DBM)
- 10.1.1.3. Synthetic
- 10.1.1.4. Xenograft
- 10.1.2. Platelet Rich Plasma (PRP)
- 10.1.3. Growth Factors
- 10.1.4. Cell-based Matrices
- 10.1.5. Bone Marrow Aspirate Concentrates (BMAC)
- 10.1.6. Others
- 10.1.1. Bone Graft Substitutes
- 10.2. Market Analysis, Insights and Forecast - By Application
- 10.2.1. Spinal Fusion
- 10.2.2. Non Fusion Procedures
- 10.2.3. Fracture Repair
- 10.2.4. Scoliosis Correction
- 10.2.5. Others
- 10.3. Market Analysis, Insights and Forecast - By End User
- 10.3.1. Hospitals & ASCs
- 10.3.2. Specialty Orthopedic & Spine Clinics
- 10.3.3. Others
- 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.4.1. GCC
- 10.4.2. South Africa
- 10.4.3. Rest of the Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Medtronic
- 11.2.2. Stryker
- 11.2.3. Johnson & Johnson
- 11.2.4. Globus Medical
- 11.2.5. Xtant Medical
- 11.2.6. Zimmer Biomet
- 11.2.7. Biomatlante.
- 11.2.8. Biogennix, LLC.
